451 reports of this reaction
1.7% of all HYDROXYZINE HYDROCHLORIDE ORAL reports
#14 most reported adverse reaction
DERMATITIS ATOPIC is the #14 most commonly reported adverse reaction for HYDROXYZINE HYDROCHLORIDE ORAL, manufactured by ANI Pharmaceuticals, Inc.. There are 451 FDA adverse event reports linking HYDROXYZINE HYDROCHLORIDE ORAL to DERMATITIS ATOPIC. This represents approximately 1.7% of all 26,851 adverse event reports for this drug.
Patients taking HYDROXYZINE HYDROCHLORIDE ORAL who experience dermatitis atopic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DERMATITIS ATOPIC is a less commonly reported adverse event for HYDROXYZINE HYDROCHLORIDE ORAL, but still significant enough to appear in the safety profile.
In addition to dermatitis atopic, the following adverse reactions have been reported for HYDROXYZINE HYDROCHLORIDE ORAL:
The following drugs have also been linked to dermatitis atopic in FDA adverse event reports:
DERMATITIS ATOPIC has been reported as an adverse event in 451 FDA reports for HYDROXYZINE HYDROCHLORIDE ORAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DERMATITIS ATOPIC accounts for approximately 1.7% of all adverse event reports for HYDROXYZINE HYDROCHLORIDE ORAL, making it a notable side effect.
If you experience dermatitis atopic while taking HYDROXYZINE HYDROCHLORIDE ORAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.